TransCode Therapeutics Acquires Option for Radiotheranostic Technology
19 mai 2022 09h00 HE
|
TransCode Therapeutics, Inc.
BOSTON, May 19, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to defeating cancer using RNA therapeutics, is pleased to announce its...
TransCode Therapeutics Reports First Quarter 2022 Results; Provides Business Update
16 mai 2022 08h30 HE
|
TransCode Therapeutics, Inc.
BOSTON, May 16, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to defeating cancer using RNA therapeutics, today reported financial results...
TransCode Therapeutics’ CTO, Dr. Zdravka Medarova, to Moderate 7th Annual RNA Medicine Symposium
13 avr. 2022 09h00 HE
|
TransCode Therapeutics, Inc.
BOSTON, April 13, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to defeating cancer using RNA therapeutics, is pleased to announce that its...
TransCode Therapeutics Reports 2021 Results; Provides Business Update
31 mars 2022 16h30 HE
|
TransCode Therapeutics, Inc.
BOSTON, March 31, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to defeating cancer using RNA therapeutics, today reported financial...
TransCode Therapeutics Interview to Air on Bloomberg U.S. on the RedChip Money Report®
25 mars 2022 12h00 HE
|
TransCode Therapeutics, Inc.
BOSTON, March 25, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a biopharmaceutical company committed to defeating cancer using RNA therapeutics, today announced that an...
TransCode Therapeutics Announces Article Published in the Journal Cancers Detailing the Potential for Short RNA-based Drugs in Cancer and a Broad Range of Disorders
23 mars 2022 09h00 HE
|
TransCode Therapeutics, Inc.
BOSTON, March 23, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to defeating cancer using RNA therapeutics, in collaboration with teams...
TransCode Therapeutics Announces Expansion of Global RNA Oncology Patent Portfolio
14 févr. 2022 09h00 HE
|
TransCode Therapeutics, Inc.
BOSTON, Feb. 14, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to defeating cancer using RNA therapeutics, today announced that it has...
CORRECTION --TransCode Therapeutics
10 févr. 2022 09h46 HE
|
TransCode Therapeutics, Inc.
BOSTON, Feb. 10, 2022 (GLOBE NEWSWIRE) -- In a release issued under the headline "TransCode Therapeutics to Present at 2020 BIO CEO & INVESTOR CONFERENCE" earlier today by TransCode...
TransCode Therapeutics to Present at 2020 BIO CEO & INVESTOR CONFERENCE
10 févr. 2022 08h30 HE
|
TransCode Therapeutics, Inc.
BOSTON, Feb. 10, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) today announced that it will be presenting at the 2022 BIO CEO & Investor Conference. TransCode’s Chief...
TransCode Therapeutics To Participate at H.C. Wainwright BioConnect Conference
06 janv. 2022 15h17 HE
|
TransCode Therapeutics, Inc.
BOSTON, Jan. 06, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) today announced that it will be attending and presenting at the H.C. Wainwright BioConnect Conference....